首页 > 最新文献

BMC Cancer最新文献

英文 中文
Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology. 198例儿科实体瘤诊断时进行大型基因组研究的临床影响:一项以精准肿瘤学的实际可行性为目标的单中心研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-21 DOI: 10.1186/s12885-024-13034-7
Juliette Simon, Damien Reita, Eric Guerin, Benoit Lhermitte, Noelle Weingertner, François Lefebvre, Marie Karanian, Julien Masliah-Planchon, Veronique Lindner, Alina Onea, Sarah Jannier, Alexandra Salmon, Guillaume Bergthold, Florence Vincent, Marlène Deschuyter, Marie-Odile Barbaza, Natacha Entz-Werlé

Introduction: Faced to the growing development of collecting systematic molecular analyses in relapsed pediatric cancers to transform their targeted matched therapies, this study aimed to assess the clinical and therapeutic indications of systematic diagnostic genomic explorations performed in pediatric solid cancers to determine which type of screening and if it afford at relapse time an accurate targeted strategy.

Methods: A total of 280 patients less than 22 years, referred at the University Hospitals of Strasbourg for a newly diagnosed solid tumor from January 2015 to December 2021, were prospectively genomically investigated since diagnosis. Using 7 different molecular tests going from single-gene methods (IHC, FISH, RT-PCR, Sanger sequencing, droplet digital PCR) to largescale analyses (Next-Generation sequencing, RNAsequencing and FoundationOne®CDx), we explored retrospectively the molecular findings in those pediatric solid tumors (except hematolymphoid cancers) to improve diagnosis, prognosis assessment and relapse therapeutics.

Results: One hundred and ninety-eight patients (71%) underwent molecular biology (MB) at diagnosis. Thirty-eight different histologies were grouped into cerebral tumors (30%), sarcomas (26%, bone and soft tissues), various blastomas (27%), and other entities (17%). Over a median 40-month follow-up, the overall survival rate of patients was 85% and the relapse rate 28%. Of the 326 analyses carried out, 245 abnormalities (single nucleotide variations: 50%, fusions: 25%, copy number alteration: 20%) concerning 70 oncogenes were highlighted. The overall clinical impact rate was 84%. Broad-spectrum analyses had a higher therapeutic impact (57%) than the targeted analyses (28%). 75% of broad-spectrum tests found an actionable variant conducting 23% of patients to receive rapidly a matched targeted therapy since first relapse.

Conclusion: Our experience highlighted the clinical utility of molecular profiling of solid tumors as soon as at diagnosis in children to expect improving access to innovative agents at relapse.

导言:面对在复发儿童癌症中收集系统分子分析以改变其靶向匹配疗法的日益发展,本研究旨在评估在儿童实体瘤中进行系统诊断基因组探索的临床和治疗适应症,以确定哪种类型的筛查以及是否能在复发时提供准确的靶向策略:2015年1月至2021年12月期间,斯特拉斯堡大学医院共对280名22岁以下新确诊实体瘤患者进行了前瞻性基因组学调查。我们使用7种不同的分子检测方法,从单基因方法(IHC、FISH、RT-PCR、Sanger测序、液滴数字PCR)到大规模分析(新一代测序、RNA测序和FoundationOne®CDx),对这些小儿实体瘤(血淋巴瘤除外)的分子研究结果进行了回顾性探索,以改进诊断、预后评估和复发治疗:198名患者(71%)在诊断时接受了分子生物学检查。38种不同的组织结构被分为脑肿瘤(30%)、肉瘤(26%,骨和软组织)、各种胚泡瘤(27%)和其他实体(17%)。在中位 40 个月的随访中,患者的总生存率为 85%,复发率为 28%。在所进行的 326 项分析中,有 245 项异常(单核苷酸变异:50%;融合:50%):50%,融合25%,拷贝数改变:20%)。总体临床影响率为 84%。广谱分析的治疗效果(57%)高于靶向分析(28%)。75%的广谱检测发现了可操作的变异体,使23%的患者在首次复发后迅速接受了匹配的靶向治疗:我们的经验凸显了儿童实体瘤分子图谱分析在诊断时的临床实用性,有望改善复发时获得创新药物的机会。
{"title":"Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology.","authors":"Juliette Simon, Damien Reita, Eric Guerin, Benoit Lhermitte, Noelle Weingertner, François Lefebvre, Marie Karanian, Julien Masliah-Planchon, Veronique Lindner, Alina Onea, Sarah Jannier, Alexandra Salmon, Guillaume Bergthold, Florence Vincent, Marlène Deschuyter, Marie-Odile Barbaza, Natacha Entz-Werlé","doi":"10.1186/s12885-024-13034-7","DOIUrl":"10.1186/s12885-024-13034-7","url":null,"abstract":"<p><strong>Introduction: </strong>Faced to the growing development of collecting systematic molecular analyses in relapsed pediatric cancers to transform their targeted matched therapies, this study aimed to assess the clinical and therapeutic indications of systematic diagnostic genomic explorations performed in pediatric solid cancers to determine which type of screening and if it afford at relapse time an accurate targeted strategy.</p><p><strong>Methods: </strong>A total of 280 patients less than 22 years, referred at the University Hospitals of Strasbourg for a newly diagnosed solid tumor from January 2015 to December 2021, were prospectively genomically investigated since diagnosis. Using 7 different molecular tests going from single-gene methods (IHC, FISH, RT-PCR, Sanger sequencing, droplet digital PCR) to largescale analyses (Next-Generation sequencing, RNAsequencing and FoundationOne®CDx), we explored retrospectively the molecular findings in those pediatric solid tumors (except hematolymphoid cancers) to improve diagnosis, prognosis assessment and relapse therapeutics.</p><p><strong>Results: </strong>One hundred and ninety-eight patients (71%) underwent molecular biology (MB) at diagnosis. Thirty-eight different histologies were grouped into cerebral tumors (30%), sarcomas (26%, bone and soft tissues), various blastomas (27%), and other entities (17%). Over a median 40-month follow-up, the overall survival rate of patients was 85% and the relapse rate 28%. Of the 326 analyses carried out, 245 abnormalities (single nucleotide variations: 50%, fusions: 25%, copy number alteration: 20%) concerning 70 oncogenes were highlighted. The overall clinical impact rate was 84%. Broad-spectrum analyses had a higher therapeutic impact (57%) than the targeted analyses (28%). 75% of broad-spectrum tests found an actionable variant conducting 23% of patients to receive rapidly a matched targeted therapy since first relapse.</p><p><strong>Conclusion: </strong>Our experience highlighted the clinical utility of molecular profiling of solid tumors as soon as at diagnosis in children to expect improving access to innovative agents at relapse.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How social class shapes breast cancer risk perspectives and prevention practices of Australian midlife women: a qualitative study using the concept of 'breast cancer candidacy'. 社会阶层如何影响澳大利亚中年妇女的乳腺癌风险观点和预防做法:一项使用 "乳腺癌候选资格 "概念的定性研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-21 DOI: 10.1186/s12885-024-13054-3
Samantha Batchelor, Belinda Lunnay, Sara Macdonald, Paul R Ward

Background: The increasing incidence of breast cancer and disease burden is a significant public health concern. While 30% of breast cancers could be prevented through addressing modifiable risk factors, misconceptions among women about breast cancer risks hamper primary prevention. In the absence of primary prevention, secondary prevention such as mammography increases the early detection of breast cancer and improves health outcomes. However, current population-level screening rates indicate secondary prevention is suboptimal. More effective public health efforts to improve breast cancer prevention are required. Given breast cancer is socially patterned, this work explores how social class impacts women's breast cancer prevention practices. This study uses the concepts of lay epidemiology and candidacy as a mechanism to understand women's breast cancer risk perspectives. It engages Bourdieu's relational social class theory to unpack how women's social, cultural, and structured life contexts shape these perspectives and their considerations regarding primary and secondary prevention.

Methods: In this qualitative study 43 Australian midlife women (aged 45-64 years), were interviewed to explore their understandings of breast cancer risks, how they perceived their own risk, and how this shaped their prevention behaviours. A theory-informed thematic analysis applying Bourdieu's concepts of habitus, capital, and fields to understand how women's social class positions shapes risk perspectives and prevention practices was conducted.

Results: This social class analysis showed differences in how women engage in breast cancer discourse, consider risks, and participate in breast cancer prevention. Middle-class women prioritise health promoting practices and were more likely than working-class and affluent women to attend mammography screening. Working-class women experience structural factors, like low income, stress and difficult life circumstances, which hamper primary prevention practices and for some screening is not considered or prioritised, and their decisions not to screen are less active. Affluent women often do not consider themselves at-risk due to their healthier 'lifestyles. 'They suggest that this, and their knowledge of screening benefits and harms allows them to make informed decisions not to screen.

Conclusions: Women interpret and understand breast cancer risks differently and enact prevention practices within the parameters afforded by their social class positions. These findings are useful to inform improved public health approaches regarding both modifiable breast cancer risks and increasing mammography screening. To improve equity in breast cancer prevention efforts, such approaches must respond to limitations based on social class and address structural factors that impact prevention practices.

背景:乳腺癌发病率和疾病负担的不断增加是一个重大的公共卫生问题。虽然 30% 的乳腺癌可以通过改变风险因素来预防,但妇女对乳腺癌风险的误解阻碍了一级预防。在缺乏一级预防的情况下,乳房 X 射线照相术等二级预防可提高乳腺癌的早期发现率,改善健康状况。然而,目前的人口筛查率表明二级预防并不理想。需要更有效的公共卫生工作来改善乳腺癌的预防。鉴于乳腺癌是一种社会模式,本研究探讨了社会阶层如何影响女性的乳腺癌预防实践。本研究将非专业流行病学和候选资格的概念作为了解妇女乳腺癌风险观点的机制。它采用布迪厄的社会阶层关系理论,来解读女性的社会、文化和结构化生活背景是如何形成这些观点以及她们对一级和二级预防的考虑的:在这项定性研究中,对 43 名澳大利亚中年女性(45-64 岁)进行了访谈,以探讨她们对乳腺癌风险的理解、她们如何看待自身的风险以及这种风险如何影响她们的预防行为。研究人员运用布尔迪厄的惯性、资本和领域概念进行了主题分析,以了解妇女的社会阶层地位如何影响她们的风险观点和预防行为:这项社会阶层分析表明,妇女在参与乳腺癌讨论、考虑风险和参与乳腺癌预防的方式上存在差异。中产阶级妇女优先考虑促进健康的做法,与工薪阶层妇女和富裕妇女相比,她们更有可能参加乳房 X 射线照相筛查。工薪阶层妇女经历的结构性因素,如低收入、压力和艰难的生活环境,阻碍了初级预防措施的实施,对一些妇女来说,筛查没有被考虑或被列为优先事项,她们决定不做筛查的积极性也较低。富裕的妇女往往不认为自己有风险,因为她们的'生活方式'更健康。她们认为,这一点以及她们对筛查利弊的了解使她们能够在知情的情况下做出不做筛查的决定:女性对乳腺癌风险有不同的解释和理解,并在其社会阶层所提供的参数范围内采取预防措施。这些发现有助于改进有关可改变的乳腺癌风险和增加乳房 X 线照相筛查的公共卫生方法。为了提高乳腺癌预防工作的公平性,这些方法必须应对基于社会阶层的限制,并解决影响预防实践的结构性因素。
{"title":"How social class shapes breast cancer risk perspectives and prevention practices of Australian midlife women: a qualitative study using the concept of 'breast cancer candidacy'.","authors":"Samantha Batchelor, Belinda Lunnay, Sara Macdonald, Paul R Ward","doi":"10.1186/s12885-024-13054-3","DOIUrl":"10.1186/s12885-024-13054-3","url":null,"abstract":"<p><strong>Background: </strong>The increasing incidence of breast cancer and disease burden is a significant public health concern. While 30% of breast cancers could be prevented through addressing modifiable risk factors, misconceptions among women about breast cancer risks hamper primary prevention. In the absence of primary prevention, secondary prevention such as mammography increases the early detection of breast cancer and improves health outcomes. However, current population-level screening rates indicate secondary prevention is suboptimal. More effective public health efforts to improve breast cancer prevention are required. Given breast cancer is socially patterned, this work explores how social class impacts women's breast cancer prevention practices. This study uses the concepts of lay epidemiology and candidacy as a mechanism to understand women's breast cancer risk perspectives. It engages Bourdieu's relational social class theory to unpack how women's social, cultural, and structured life contexts shape these perspectives and their considerations regarding primary and secondary prevention.</p><p><strong>Methods: </strong>In this qualitative study 43 Australian midlife women (aged 45-64 years), were interviewed to explore their understandings of breast cancer risks, how they perceived their own risk, and how this shaped their prevention behaviours. A theory-informed thematic analysis applying Bourdieu's concepts of habitus, capital, and fields to understand how women's social class positions shapes risk perspectives and prevention practices was conducted.</p><p><strong>Results: </strong>This social class analysis showed differences in how women engage in breast cancer discourse, consider risks, and participate in breast cancer prevention. Middle-class women prioritise health promoting practices and were more likely than working-class and affluent women to attend mammography screening. Working-class women experience structural factors, like low income, stress and difficult life circumstances, which hamper primary prevention practices and for some screening is not considered or prioritised, and their decisions not to screen are less active. Affluent women often do not consider themselves at-risk due to their healthier 'lifestyles. 'They suggest that this, and their knowledge of screening benefits and harms allows them to make informed decisions not to screen.</p><p><strong>Conclusions: </strong>Women interpret and understand breast cancer risks differently and enact prevention practices within the parameters afforded by their social class positions. These findings are useful to inform improved public health approaches regarding both modifiable breast cancer risks and increasing mammography screening. To improve equity in breast cancer prevention efforts, such approaches must respond to limitations based on social class and address structural factors that impact prevention practices.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis. 免疫检查点抑制剂治疗晚期或复发性子宫内膜癌的疗效和安全性:系统综述和网络荟萃分析。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-21 DOI: 10.1186/s12885-024-13058-z
Danxue Huang, Su Li, Yang Bai, Yan Wang

Background: Currently, several randomized controlled trials (RCTs) have been conducted to investigate the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer; however, the optimal treatment strategy remains undetermined.

Methods: A comprehensive search of online databases was conducted to identify RCTs published until December 31, 2023. Network meta-analysis was performed to evaluate PFS, OS, TRAEs, irAEs, and the ranking of different treatment regimens.

Results: A total of 2702 patients from five RCTs (six reports) were included in the analysis. The combination therapy of ICIs significantly prolonged PFS (HR = 0.69, 95%CI 0.63-0.76, p < 0.0001) and OS (HR = 0.73, 95%CI 0.63-0.85, p < 0.0001) in the overall population. Among the different ICIs combinations evaluated, Durva-Olap-CP exhibited superior efficacy for both PFS and OS outcomes. In the pMMR population, both Durva-Olap-CP and Pembro-CP significantly reduced the risk of disease progression or death compared to Avelu-CP and Atezo-CP treatments; however, no significant differences were observed among various ICI combination therapies in patients with dMMR. In the dMMR population, Dostar-CP demonstrates a 42.2% probability of achieving first rank in terms of PFS, whereas in the pMMR population, Pembro-CP exhibits a 60% likelihood of securing the top position. Importantly, the toxicity associated with ICIs combination therapy was manageable and well-tolerated.

Conclusions: The combination of ICIs and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer has demonstrated superior survival outcomes compared to chemotherapy alone. Durva-Olap-CP exhibited the most favorable PFS and OS benefits in the overall population. In patients with dMMR, Dostar-CP showed the greatest improvement in PFS, while Pembro-CP demonstrated the most pronounced PFS benefit in patients with pMMR.

背景:目前,已有多项随机对照试验(RCT)研究了将免疫检查点抑制剂(ICIs)与化疗相结合作为晚期或复发性子宫内膜癌一线治疗的疗效;然而,最佳治疗策略仍未确定:方法:对在线数据库进行了全面检索,以确定截至2023年12月31日发表的RCT。方法:对截至2023年12月31日发表的RCT进行全面检索,并进行网络荟萃分析,以评估PFS、OS、TRAEs、irAEs以及不同治疗方案的排名:共有来自5项RCT(6份报告)的2702名患者被纳入分析。作为晚期或复发性子宫内膜癌的一线治疗方法,ICIs与化疗的联合治疗显示出了优于单独化疗的生存效果。Durva-Olap-CP在总体人群中显示出最有利的PFS和OS效益。在dMMR患者中,Dostar-CP对PFS的改善最大,而在pMMR患者中,Pembro-CP对PFS的益处最明显。
{"title":"Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.","authors":"Danxue Huang, Su Li, Yang Bai, Yan Wang","doi":"10.1186/s12885-024-13058-z","DOIUrl":"10.1186/s12885-024-13058-z","url":null,"abstract":"<p><strong>Background: </strong>Currently, several randomized controlled trials (RCTs) have been conducted to investigate the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer; however, the optimal treatment strategy remains undetermined.</p><p><strong>Methods: </strong>A comprehensive search of online databases was conducted to identify RCTs published until December 31, 2023. Network meta-analysis was performed to evaluate PFS, OS, TRAEs, irAEs, and the ranking of different treatment regimens.</p><p><strong>Results: </strong>A total of 2702 patients from five RCTs (six reports) were included in the analysis. The combination therapy of ICIs significantly prolonged PFS (HR = 0.69, 95%CI 0.63-0.76, p < 0.0001) and OS (HR = 0.73, 95%CI 0.63-0.85, p < 0.0001) in the overall population. Among the different ICIs combinations evaluated, Durva-Olap-CP exhibited superior efficacy for both PFS and OS outcomes. In the pMMR population, both Durva-Olap-CP and Pembro-CP significantly reduced the risk of disease progression or death compared to Avelu-CP and Atezo-CP treatments; however, no significant differences were observed among various ICI combination therapies in patients with dMMR. In the dMMR population, Dostar-CP demonstrates a 42.2% probability of achieving first rank in terms of PFS, whereas in the pMMR population, Pembro-CP exhibits a 60% likelihood of securing the top position. Importantly, the toxicity associated with ICIs combination therapy was manageable and well-tolerated.</p><p><strong>Conclusions: </strong>The combination of ICIs and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer has demonstrated superior survival outcomes compared to chemotherapy alone. Durva-Olap-CP exhibited the most favorable PFS and OS benefits in the overall population. In patients with dMMR, Dostar-CP showed the greatest improvement in PFS, while Pembro-CP demonstrated the most pronounced PFS benefit in patients with pMMR.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing personalized oncology: a systematic review on the integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients. 推进个性化肿瘤学:关于将人工智能纳入乳腺癌患者新辅助治疗监测的系统综述。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-21 DOI: 10.1186/s12885-024-13049-0
Rachida Hachache, Ali Yahyaouy, Jamal Riffi, Hamid Tairi, Soukayna Abibou, Mohammed El Adoui, Mohammed Benjelloun

Purpose: Despite suffering from the same disease, each patient exhibits a distinct microbiological profile and variable reactivity to prescribed treatments. Most doctors typically use a standardized treatment approach for all patients suffering from a specific disease. Consequently, the challenge lies in the effectiveness of this standardized treatment and in adapting it to each individual patient. Personalized medicine is an emerging field in which doctors use diagnostic tests to identify the most effective medical treatments for each patient. Prognosis, disease monitoring, and treatment planning rely on manual, error-prone methods. Artificial intelligence (AI) uses predictive techniques capable of automating prognostic and monitoring processes, thus reducing the error rate associated with conventional methods.

Methods: This paper conducts an analysis of current literature, encompassing the period from January 2015 to 2023, based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Results: In assessing 25 pertinent studies concerning predicting neoadjuvant treatment (NAT) response in breast cancer (BC) patients, the studies explored various imaging modalities (Magnetic Resonance Imaging, Ultrasound, etc.), evaluating results based on accuracy, sensitivity, and area under the curve. Additionally, the technologies employed, such as machine learning (ML), deep learning (DL), statistics, and hybrid models, were scrutinized. The presentation of datasets used for predicting complete pathological response (PCR) was also considered.

Conclusion: This paper seeks to unveil crucial insights into the application of AI techniques in personalized oncology, particularly in the monitoring and prediction of responses to NAT for BC patients. Finally, the authors suggest avenues for future research into AI-based monitoring systems.

目的:尽管患的是同一种疾病,但每位患者的微生物学特征各不相同,对处方治疗的反应也不尽相同。大多数医生通常对所有特定疾病患者采用标准化治疗方法。因此,这种标准化治疗方法的有效性以及如何根据每个病人的具体情况进行调整就成了难题。个性化医疗是一个新兴领域,医生通过诊断测试为每位患者确定最有效的治疗方法。预后判断、疾病监测和治疗计划都依赖于人工和容易出错的方法。人工智能(AI)使用的预测技术能够使预后和监测过程自动化,从而降低与传统方法相关的错误率:本文根据系统综述和荟萃分析的首选报告项目(PRISMA),对2015年1月至2023年期间的现有文献进行了分析:在评估25项关于预测乳腺癌(BC)患者新辅助治疗(NAT)反应的相关研究时,这些研究探讨了各种成像模式(磁共振成像、超声波等),并根据准确性、灵敏度和曲线下面积对结果进行了评估。此外,还仔细研究了所采用的技术,如机器学习(ML)、深度学习(DL)、统计学和混合模型。还考虑了用于预测完全病理反应(PCR)的数据集的展示:本文旨在揭示人工智能技术在个性化肿瘤学中应用的重要见解,尤其是在监测和预测 BC 患者对 NAT 的反应方面。最后,作者为基于人工智能的监测系统的未来研究提出了建议。
{"title":"Advancing personalized oncology: a systematic review on the integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients.","authors":"Rachida Hachache, Ali Yahyaouy, Jamal Riffi, Hamid Tairi, Soukayna Abibou, Mohammed El Adoui, Mohammed Benjelloun","doi":"10.1186/s12885-024-13049-0","DOIUrl":"10.1186/s12885-024-13049-0","url":null,"abstract":"<p><strong>Purpose: </strong>Despite suffering from the same disease, each patient exhibits a distinct microbiological profile and variable reactivity to prescribed treatments. Most doctors typically use a standardized treatment approach for all patients suffering from a specific disease. Consequently, the challenge lies in the effectiveness of this standardized treatment and in adapting it to each individual patient. Personalized medicine is an emerging field in which doctors use diagnostic tests to identify the most effective medical treatments for each patient. Prognosis, disease monitoring, and treatment planning rely on manual, error-prone methods. Artificial intelligence (AI) uses predictive techniques capable of automating prognostic and monitoring processes, thus reducing the error rate associated with conventional methods.</p><p><strong>Methods: </strong>This paper conducts an analysis of current literature, encompassing the period from January 2015 to 2023, based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).</p><p><strong>Results: </strong>In assessing 25 pertinent studies concerning predicting neoadjuvant treatment (NAT) response in breast cancer (BC) patients, the studies explored various imaging modalities (Magnetic Resonance Imaging, Ultrasound, etc.), evaluating results based on accuracy, sensitivity, and area under the curve. Additionally, the technologies employed, such as machine learning (ML), deep learning (DL), statistics, and hybrid models, were scrutinized. The presentation of datasets used for predicting complete pathological response (PCR) was also considered.</p><p><strong>Conclusion: </strong>This paper seeks to unveil crucial insights into the application of AI techniques in personalized oncology, particularly in the monitoring and prediction of responses to NAT for BC patients. Finally, the authors suggest avenues for future research into AI-based monitoring systems.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11495077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment. 基线贫血对多西他赛和雷莫芦单抗治疗晚期非小细胞肺癌疗效的影响
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-21 DOI: 10.1186/s12885-024-13070-3
Yoshitaka Saito, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara

Background: Docetaxel (DOC) and ramucirumab (RAM) is one of the most effective regimens for advanced non-small cell lung cancer (NSCLC) treatment. In our previous study, baseline anemia was identified as a preventive factor against the development of severe adverse effects during the first treatment cycle. It was hypothesized that anemia directly promotes tumor angiogenesis, leading to the elevation of RAM efficacy with increased DOC delivery to tumors, while reducing DOC delivery to other organs, potentially mitigating severe adverse effects. If this hypothesis is correct, patients with baseline anemia may have better clinical outcomes than those with normal hemoglobin levels. In this study, we aimed to investigate the effect of baseline anemia on the efficacy of DOC + RAM in treating advanced NSCLC in a real-word setting.

Methods: Patients with advanced NSCLC receiving DOC + RAM (n = 72) were retrospectively assessed. They were categorized into a control group with normal baseline hemoglobin levels and an anemia group with baseline anemia. The primary endpoint was progression-free survival (PFS) evaluation.

Results: Patients in the anemia group had a significantly shorter PFS than that of patients in the control group (median PFS: 3.2 and 6.2 months; 95% confidence interval [CI]: 2.2-4.8 and 4.3-9.9 months, respectively;P = 0.008). In addition, the disease control rate in the anemia group was 65.8%, which was significantly lower than that in the control group (93.6%; P = 0.007). Overall survival tended to be shorter in patients with anemia than in controls, although the difference was not statistically significant (P = 0.07). Multivariate Cox hazard analysis suggested that baseline anemia was a singular risk factor for poor PFS (adjusted hazard ratio 1.84, 95% CI 1.08-3.13; P = 0.02). The incidence of severe adverse effects did not differ between the two groups.

Conclusions: This study suggests that the PFS of patients with anemia treated with DOC + RAM for advanced NSCLC is shorter than that of those without the symptoms.

背景:多西他赛(DOC)联合雷莫芦单抗(RAM)是治疗晚期非小细胞肺癌(NSCLC)最有效的方案之一。在我们之前的研究中,基线贫血被认为是第一个治疗周期中出现严重不良反应的一个预防因素。我们假设贫血会直接促进肿瘤血管生成,从而提高 RAM 的疗效,增加 DOC 向肿瘤的输送,同时减少 DOC 向其他器官的输送,从而减轻严重不良反应。如果这一假设是正确的,那么基线贫血患者的临床疗效可能比血红蛋白水平正常的患者更好。在本研究中,我们旨在调查基线贫血对 DOC + RAM 治疗晚期 NSCLC 疗效的影响:我们对接受 DOC + RAM 治疗的晚期 NSCLC 患者(n = 72)进行了回顾性评估。他们被分为基线血红蛋白水平正常的对照组和基线贫血的贫血组。主要终点是无进展生存期(PFS)评估:贫血组患者的无进展生存期明显短于对照组(中位无进展生存期:分别为3.2个月和6.2个月;95%置信区间[CI]:分别为2.2-4.8个月和4.3-9.9个月;P = 0.008)。此外,贫血组的疾病控制率为65.8%,明显低于对照组(93.6%;P = 0.007)。贫血患者的总生存期往往短于对照组,但差异无统计学意义(P = 0.07)。多变量 Cox 危险分析表明,基线贫血是 PFS 较差的单一危险因素(调整后危险比 1.84,95% CI 1.08-3.13;P = 0.02)。两组患者的严重不良反应发生率没有差异:本研究表明,晚期NSCLC贫血患者接受DOC+RAM治疗的PFS短于无贫血症状的患者。
{"title":"Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advanced non-small cell lung cancer treatment.","authors":"Yoshitaka Saito, Yoh Takekuma, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Mitsuru Sugawara","doi":"10.1186/s12885-024-13070-3","DOIUrl":"10.1186/s12885-024-13070-3","url":null,"abstract":"<p><strong>Background: </strong>Docetaxel (DOC) and ramucirumab (RAM) is one of the most effective regimens for advanced non-small cell lung cancer (NSCLC) treatment. In our previous study, baseline anemia was identified as a preventive factor against the development of severe adverse effects during the first treatment cycle. It was hypothesized that anemia directly promotes tumor angiogenesis, leading to the elevation of RAM efficacy with increased DOC delivery to tumors, while reducing DOC delivery to other organs, potentially mitigating severe adverse effects. If this hypothesis is correct, patients with baseline anemia may have better clinical outcomes than those with normal hemoglobin levels. In this study, we aimed to investigate the effect of baseline anemia on the efficacy of DOC + RAM in treating advanced NSCLC in a real-word setting.</p><p><strong>Methods: </strong>Patients with advanced NSCLC receiving DOC + RAM (n = 72) were retrospectively assessed. They were categorized into a control group with normal baseline hemoglobin levels and an anemia group with baseline anemia. The primary endpoint was progression-free survival (PFS) evaluation.</p><p><strong>Results: </strong>Patients in the anemia group had a significantly shorter PFS than that of patients in the control group (median PFS: 3.2 and 6.2 months; 95% confidence interval [CI]: 2.2-4.8 and 4.3-9.9 months, respectively;P = 0.008). In addition, the disease control rate in the anemia group was 65.8%, which was significantly lower than that in the control group (93.6%; P = 0.007). Overall survival tended to be shorter in patients with anemia than in controls, although the difference was not statistically significant (P = 0.07). Multivariate Cox hazard analysis suggested that baseline anemia was a singular risk factor for poor PFS (adjusted hazard ratio 1.84, 95% CI 1.08-3.13; P = 0.02). The incidence of severe adverse effects did not differ between the two groups.</p><p><strong>Conclusions: </strong>This study suggests that the PFS of patients with anemia treated with DOC + RAM for advanced NSCLC is shorter than that of those without the symptoms.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applying the Health Belief Model to cervical cancer screening uptake among women in Ethiopia: a systematic review and meta-analysis. 将健康信念模式应用于埃塞俄比亚妇女接受宫颈癌筛查的情况:系统回顾和荟萃分析。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-19 DOI: 10.1186/s12885-024-13055-2
Amlaku Nigusie Yirsaw, Mitiku Tefera, Eyob Ketema Bogale, Tadele Fentabel Anagaw, Misganaw Guadie Tiruneh, Eneyew Talie Fenta, Destaw Endeshaw, Ousman Adal, Abiyu Abadi Tareke, Lijalem Jemberu, Eyob Getachew, Asnake Gashaw Belayneh, Getnet Alemu Andarge, Kedir Seid, Gebeyehu Lakew

Background: Cervical cancer is a leading cause of cancer mortality globally, especially in Africa, including Ethiopia. This review assesses predictors of cervical cancer screening uptake among Ethiopian-eligible women using the Health Belief Model. Higher education levels, perceived susceptibility, severity, and fewer barriers are associated with increased screening. Effective HBM-based interventions could enhance screening rates, potentially reducing cervical cancer incidence and mortality.

Objective: The review aimed to synthesize the existing literature on the prevalence of Cervical Cancer Screening Service Uptake and Associated Factors among Eligible Women using the Health belief model in Ethiopia, 2024.

Method: This systematic review and meta-analysis searched Google Scholar, PubMed, and the Cochrane Library engine. Key terms such as "Cervical cancer screening", "uptake", "utilization", "factors", "barriers", and "Ethiopia" were used to identify relevant articles. Data extraction utilized a detailed form, and the methodological quality of each study was assessed using the JBI quality appraisal checklist for cross-sectional studies. Statistical analysis was conducted using STATA version 17, and the meta-analysis findings were presented using forest plots and tables.

Result: The result of seven studies revealed that the overall prevalence of Cervical Cancer Screening Service Uptake among eligible women in Ethiopia was 21% (95% CI: 15%-27%). Factors independently associated with Cancer Screening Service Uptake included: Knowledge (OR = 4.563, 95% CI: 1.012-4.188), age 30 up to 49 (OR = 4.106, 95% CI: 1.562-6.650), history of STD (OR = 2.59, 95% CI: 1.694-4.486), high perceived susceptibility (OR = 3.814, 95% CI: 2.312-5.316), high perceived severity (OR = 2.603, 95% CI: 2.203-3.003), low perceived barrier (OR = 4.390, 95% CI: 1.331-8.449), high perceived self-efficacy (OR = 4.77, 95% CI: 4.102-5.431), high perceived benefit (OR = 3.67, 95% CI: 1.851-5.489), and education level greater than primary level (OR = 4.497, 95% CI: 3.619-5.375).

Conclusion: Cervical cancer is a major public health challenge in Ethiopia. Consequently, there is a pressing need for the governments to formulate comprehensive, multi-sectorial policies and strategies. These initiatives should be designed to address the problem influenced by interconnected factors, to reduce the prevalence of cervical cancer in Ethiopia.

背景:宫颈癌是全球癌症死亡的主要原因,尤其是在非洲,包括埃塞俄比亚。本综述采用健康信念模型评估了埃塞俄比亚符合条件的妇女接受宫颈癌筛查的预测因素。较高的教育水平、感知到的易感性、严重性和较少的障碍与筛查率的提高有关。基于健康信念模型的有效干预措施可以提高筛查率,从而降低宫颈癌的发病率和死亡率:本综述旨在综合现有文献,研究 2024 年埃塞俄比亚符合条件的妇女使用健康信念模型接受宫颈癌筛查服务的普遍性及相关因素:本系统综述和荟萃分析检索了 Google Scholar、PubMed 和 Cochrane Library 引擎。使用 "宫颈癌筛查"、"接受"、"利用"、"因素"、"障碍 "和 "埃塞俄比亚 "等关键词来确定相关文章。数据提取使用了一份详细的表格,并使用 JBI 横向研究质量评估清单对每项研究的方法学质量进行了评估。统计分析采用 STATA 17 版本,荟萃分析结果采用森林图和表格的形式呈现:七项研究结果显示,埃塞俄比亚符合条件的妇女接受宫颈癌筛查服务的总体比例为 21%(95% CI:15%-27%)。与接受癌症筛查服务独立相关的因素包括知识(OR = 4.563,95% CI:1.012-4.188)、年龄 30-49 岁(OR = 4.106,95% CI:1.562-6.650)、性病史(OR = 2.59,95% CI:1.694-4.486)、高感知易感性(OR = 3.814,95% CI:2.312-5.316)、高感知严重性(OR = 2.603,95% CI:2.203-3.003)、低感知障碍(OR = 3.814,95% CI:2.312-5.316)、高感知易感性(OR = 3.814,95% CI:2.312-5.316)。003)、低感知障碍(OR = 4.390,95% CI:1.331-8.449)、高感知自我效能(OR = 4.77,95% CI:4.102-5.431)、高感知获益(OR = 3.67,95% CI:1.851-5.489)、教育程度高于小学(OR = 4.497,95% CI:3.619-5.375):宫颈癌是埃塞俄比亚公共卫生的一大挑战。因此,政府迫切需要制定全面的多部门政策和战略。这些举措应旨在解决受相互关联因素影响的问题,以降低宫颈癌在埃塞俄比亚的发病率。
{"title":"Applying the Health Belief Model to cervical cancer screening uptake among women in Ethiopia: a systematic review and meta-analysis.","authors":"Amlaku Nigusie Yirsaw, Mitiku Tefera, Eyob Ketema Bogale, Tadele Fentabel Anagaw, Misganaw Guadie Tiruneh, Eneyew Talie Fenta, Destaw Endeshaw, Ousman Adal, Abiyu Abadi Tareke, Lijalem Jemberu, Eyob Getachew, Asnake Gashaw Belayneh, Getnet Alemu Andarge, Kedir Seid, Gebeyehu Lakew","doi":"10.1186/s12885-024-13055-2","DOIUrl":"10.1186/s12885-024-13055-2","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a leading cause of cancer mortality globally, especially in Africa, including Ethiopia. This review assesses predictors of cervical cancer screening uptake among Ethiopian-eligible women using the Health Belief Model. Higher education levels, perceived susceptibility, severity, and fewer barriers are associated with increased screening. Effective HBM-based interventions could enhance screening rates, potentially reducing cervical cancer incidence and mortality.</p><p><strong>Objective: </strong>The review aimed to synthesize the existing literature on the prevalence of Cervical Cancer Screening Service Uptake and Associated Factors among Eligible Women using the Health belief model in Ethiopia, 2024.</p><p><strong>Method: </strong>This systematic review and meta-analysis searched Google Scholar, PubMed, and the Cochrane Library engine. Key terms such as \"Cervical cancer screening\", \"uptake\", \"utilization\", \"factors\", \"barriers\", and \"Ethiopia\" were used to identify relevant articles. Data extraction utilized a detailed form, and the methodological quality of each study was assessed using the JBI quality appraisal checklist for cross-sectional studies. Statistical analysis was conducted using STATA version 17, and the meta-analysis findings were presented using forest plots and tables.</p><p><strong>Result: </strong>The result of seven studies revealed that the overall prevalence of Cervical Cancer Screening Service Uptake among eligible women in Ethiopia was 21% (95% CI: 15%-27%). Factors independently associated with Cancer Screening Service Uptake included: Knowledge (OR = 4.563, 95% CI: 1.012-4.188), age 30 up to 49 (OR = 4.106, 95% CI: 1.562-6.650), history of STD (OR = 2.59, 95% CI: 1.694-4.486), high perceived susceptibility (OR = 3.814, 95% CI: 2.312-5.316), high perceived severity (OR = 2.603, 95% CI: 2.203-3.003), low perceived barrier (OR = 4.390, 95% CI: 1.331-8.449), high perceived self-efficacy (OR = 4.77, 95% CI: 4.102-5.431), high perceived benefit (OR = 3.67, 95% CI: 1.851-5.489), and education level greater than primary level (OR = 4.497, 95% CI: 3.619-5.375).</p><p><strong>Conclusion: </strong>Cervical cancer is a major public health challenge in Ethiopia. Consequently, there is a pressing need for the governments to formulate comprehensive, multi-sectorial policies and strategies. These initiatives should be designed to address the problem influenced by interconnected factors, to reduce the prevalence of cervical cancer in Ethiopia.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. 派罗替尼联合甲氨蝶呤治疗重度预处理的HER2阳性转移性乳腺癌:一项单臂II期研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1186/s12885-024-13041-8
Jiaxuan Liu, Maiyue He, Mingxia Jiang, Shihan Zhou, Mengqi Zhang, Yiqun Li, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Fei Ma, Binghe Xu, Qiao Li

Background: Exploration of novel combination mode of pyrotinib and chemotherapy for heavily pretreated HER2-positive metastatic breast cancer (MBC) and how to balance survival benefits and compliance are still urgent problems in clinical practice. The current single-arm prospective phase II study aimed to evaluate the efficacy and safety of pyrotinib in combination with metronomic oral etoposide in heavily pretreated HER2-positive MBC.

Methods: HER2-positive MBC patients previously treated with trastuzumab were enrolled to receive oral pyrotinib 400 mg per day and metronomic oral etoposide 50 mg per day d1-21 every 28 days, until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), overall survival (OS), and safety.

Results: 22 patients were enrolled with a median of 4 prior treatment regimens for MBC. During the follow-up of 20 evaluable patients, the median PFS was 9.0 months (95% CI, 7.6-10.4 months), and the median OS was 27.0 months (95%CI, 20.9-33.1 months). The ORR was 30% (6/20), the DCR was 80% (16/20), and the CBR was 65% (13/20). The most common grade 3 adverse events (AEs) included nausea (15%), vomiting (15%), diarrhea (5%), anemia (5%), and peripheral neuropathy (5%). No grade 4 or lethal AEs were observed.

Conclusion: The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity.

Trial registration: Registry number: NCT03923179. Registered April 18, 2019.

背景:探索吡罗替尼与化疗联合治疗重度预处理HER2阳性转移性乳腺癌(MBC)的新模式,以及如何平衡生存获益与依从性仍是临床实践中亟待解决的问题。方法:既往接受过曲妥珠单抗治疗的HER2阳性MBC患者入组,接受每天400毫克的吡罗替尼口服和每天50毫克的依托泊苷口服,每28天为1-21天,直到疾病进展或出现不可接受的毒性。主要终点是无进展生存期(PFS)。次要终点为客观反应率(ORR)、疾病控制率(DCR)、临床获益率(CBR)、总生存期(OS)和安全性。在对20名可评估患者的随访中,中位PFS为9.0个月(95%CI,7.6-10.4个月),中位OS为27.0个月(95%CI,20.9-33.1个月)。ORR为30%(6/20),DCR为80%(16/20),CBR为65%(13/20)。最常见的3级不良事件(AEs)包括恶心(15%)、呕吐(15%)、腹泻(5%)、贫血(5%)和周围神经病变(5%)。未观察到4级或致死性AE:结论:派罗替尼联合甲粒口服依托泊苷治疗重度预处理的HER2阳性MBC取得了良好的临床疗效,毒性可接受且可控:注册号:NCT03923179NCT03923179。注册时间:2019年4月18日。
{"title":"Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study.","authors":"Jiaxuan Liu, Maiyue He, Mingxia Jiang, Shihan Zhou, Mengqi Zhang, Yiqun Li, Shanshan Chen, Ruigang Cai, Hongnan Mo, Bo Lan, Fei Ma, Binghe Xu, Qiao Li","doi":"10.1186/s12885-024-13041-8","DOIUrl":"https://doi.org/10.1186/s12885-024-13041-8","url":null,"abstract":"<p><strong>Background: </strong>Exploration of novel combination mode of pyrotinib and chemotherapy for heavily pretreated HER2-positive metastatic breast cancer (MBC) and how to balance survival benefits and compliance are still urgent problems in clinical practice. The current single-arm prospective phase II study aimed to evaluate the efficacy and safety of pyrotinib in combination with metronomic oral etoposide in heavily pretreated HER2-positive MBC.</p><p><strong>Methods: </strong>HER2-positive MBC patients previously treated with trastuzumab were enrolled to receive oral pyrotinib 400 mg per day and metronomic oral etoposide 50 mg per day d1-21 every 28 days, until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), overall survival (OS), and safety.</p><p><strong>Results: </strong>22 patients were enrolled with a median of 4 prior treatment regimens for MBC. During the follow-up of 20 evaluable patients, the median PFS was 9.0 months (95% CI, 7.6-10.4 months), and the median OS was 27.0 months (95%CI, 20.9-33.1 months). The ORR was 30% (6/20), the DCR was 80% (16/20), and the CBR was 65% (13/20). The most common grade 3 adverse events (AEs) included nausea (15%), vomiting (15%), diarrhea (5%), anemia (5%), and peripheral neuropathy (5%). No grade 4 or lethal AEs were observed.</p><p><strong>Conclusion: </strong>The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity.</p><p><strong>Trial registration: </strong>Registry number: NCT03923179. Registered April 18, 2019.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11487706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer. 在进展期后继续使用相同的程序性死亡-1抑制剂是治疗晚期胃癌的一种新选择。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1186/s12885-024-13063-2
Jiasong Li, Fang Ding, Shasha Zhang, Yuanyuan Jia, Tianhang Zhang, Siqi Wang, Qingyi Liu, Zhanjun Guo

Background: Gastric cancer is a significant global malignancy with poor prognosis. Although the emergence of immune checkpoint inhibitors (ICIs) prolonged the duration of survival, resistance and progression are inevitable. We aim to evaluate the effectiveness of programmed death-1 (PD-1) inhibitors in immunotherapy beyond progression (IBP).

Method: We divided the advanced gastric cancer patients who received two lines immunotherapy into same regimen group (with same PD-1 inhibitor regime after IBP) and different regimen group (with different PD-1 inhibitor regime after IBP). Statistical analysis conducted to compare patient characteristics and evaluate survival differences between groups.

Result: The clinical outcome analysis showed that the same PD-1 inhibitor regime seemed to exhibit a higher disease control rate (DCR) (51.8% vs. 29.2%, P = 0.062), significantly prolonged progression-free survival 2 (PFS2) (162 vs. 75 days, P = 0.001) and overall survival (OS) (312 vs. 166 days, P = 0.022) when compared with those of cross line. In the multivariate analysis, when using different regimen group as reference, the same regimen group was found to be independently associated with improved PFS2 [hazard ratio (HR) = 0.467, 95% confidence interval (CI): 0.267-0.816, P = 0.008] and OS (HR = 0.508, 95%CI: 0.278-0.927, P = 0.027).

Conclusion: Continuation of the same type of PD-1 inhibitor regime in IBP shows clinical benefits and represents a promising therapeutic approach.

背景:胃癌是一种严重的全球性恶性肿瘤,预后较差。虽然免疫检查点抑制剂(ICIs)的出现延长了患者的生存期,但耐药和进展是不可避免的。我们旨在评估程序性死亡-1(PD-1)抑制剂在进展期后免疫治疗(IBP)中的有效性:方法:我们将接受两线免疫治疗的晚期胃癌患者分为相同方案组(IBP后使用相同的PD-1抑制剂方案)和不同方案组(IBP后使用不同的PD-1抑制剂方案)。统计分析比较了患者特征,并评估了组间生存率差异:临床结果分析表明,与交叉方案相比,相同的PD-1抑制剂方案似乎表现出更高的疾病控制率(DCR)(51.8% vs. 29.2%,P = 0.062),显著延长无进展生存期2(PFS2)(162天 vs. 75天,P = 0.001)和总生存期(OS)(312天 vs. 166天,P = 0.022)。在多变量分析中,以不同方案组为参照,发现相同方案组与PFS2[危险比(HR)=0.467,95%置信区间(CI):0.267-0.816,P=0.008]和OS(HR=0.508,95%CI:0.278-0.927,P=0.027)的改善独立相关:结论:IBP患者继续使用同一种PD-1抑制剂可获得临床疗效,是一种很有前景的治疗方法。
{"title":"Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.","authors":"Jiasong Li, Fang Ding, Shasha Zhang, Yuanyuan Jia, Tianhang Zhang, Siqi Wang, Qingyi Liu, Zhanjun Guo","doi":"10.1186/s12885-024-13063-2","DOIUrl":"10.1186/s12885-024-13063-2","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is a significant global malignancy with poor prognosis. Although the emergence of immune checkpoint inhibitors (ICIs) prolonged the duration of survival, resistance and progression are inevitable. We aim to evaluate the effectiveness of programmed death-1 (PD-1) inhibitors in immunotherapy beyond progression (IBP).</p><p><strong>Method: </strong>We divided the advanced gastric cancer patients who received two lines immunotherapy into same regimen group (with same PD-1 inhibitor regime after IBP) and different regimen group (with different PD-1 inhibitor regime after IBP). Statistical analysis conducted to compare patient characteristics and evaluate survival differences between groups.</p><p><strong>Result: </strong>The clinical outcome analysis showed that the same PD-1 inhibitor regime seemed to exhibit a higher disease control rate (DCR) (51.8% vs. 29.2%, P = 0.062), significantly prolonged progression-free survival 2 (PFS2) (162 vs. 75 days, P = 0.001) and overall survival (OS) (312 vs. 166 days, P = 0.022) when compared with those of cross line. In the multivariate analysis, when using different regimen group as reference, the same regimen group was found to be independently associated with improved PFS2 [hazard ratio (HR) = 0.467, 95% confidence interval (CI): 0.267-0.816, P = 0.008] and OS (HR = 0.508, 95%CI: 0.278-0.927, P = 0.027).</p><p><strong>Conclusion: </strong>Continuation of the same type of PD-1 inhibitor regime in IBP shows clinical benefits and represents a promising therapeutic approach.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis. HER2 阳性乳腺癌保乳手术转换中新辅助单药治疗与双 HER2 阻断的比较:一项荟萃分析。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1186/s12885-024-13052-5
Manlu Cui, Juan Fu, Qiuyun Li

Background: Neoadjuvant targeted therapy has shown that improve pathologic complete response and facilitate breast-conserving surgery, but the difference between single-agent treatment or dual-HER2 blockade to the conversion of breast-conserving surgery has not been well described.

Methods: Via the systematic literature search of PubMed, Web of Science and Cochrane Library databases, 5 eligible studies used to perform this meta-analysis, which was carried out using RevMan version 5.4.

Results: A total of 1306 patients from five randomized controlled trials were included in the analysis, revealing a significant increase in the conversion rate to breast-conserving surgery with neoadjuvant targeted therapy (OR 0.30, 95% CI 0.15-0.57; p = 0.0003). The odds ratio (OR) for single-agent treatment compared to dual-HER2 blockade was 1.04 (95% CI 0.73-1.48; p = 0.82). For pathological complete response (pCR), the OR for single-HER2 blockade versus dual-HER2 blockade was 0.43 (95% CI 0.34-0.55; p = 0.01), and for clinical response, it was 0.81 (95% CI 0.59-1.10; p = 0.17). The OR for serious adverse events between single-HER2 and dual-HER2 blockade was 0.72 (95% CI 0.55-0.95; p = 0.02). The risk ratio (RR) for pCR and the shift from mastectomy to BCS was 1.16 (95% CI 0.78-1.72; p = 0.47), while for clinical response and the shift from mastectomy to BCS, it was 2.40 (95% CI 1.44-4.01; p = 0.0008).

Conclusion: Neoadjuvant targeted treatment obviously promote the actual implementation rate of breast-conserving surgery, nevertheless, there was no statistically significant increase in single-agent treatment versus dual-HER2 blockade.

背景:新辅助靶向治疗可改善病理完全反应并促进保乳手术,但单药治疗或双HER2阻断对保乳手术转换的影响尚未得到很好的描述:方法:通过对PubMed、Web of Science和Cochrane Library数据库进行系统文献检索,采用RevMan 5.4版对5项符合条件的研究进行荟萃分析:结果表明,新辅助靶向治疗可显著提高保乳手术的转化率(OR 0.30,95% CI 0.15-0.57;P = 0.0003)。与双HER2阻断相比,单药治疗的几率比(OR)为1.04(95% CI 0.73-1.48;P = 0.82)。就病理完全反应(pCR)而言,单HER2阻断与双HER2阻断的OR值为0.43(95% CI 0.34-0.55;p = 0.01),就临床反应而言,OR值为0.81(95% CI 0.59-1.10;p = 0.17)。单HER2和双HER2阻断疗法发生严重不良事件的OR为0.72(95% CI 0.55-0.95;P = 0.02)。pCR和从乳房切除术转为BCS的风险比(RR)为1.16 (95% CI 0.78-1.72; p = 0.47),而临床反应和从乳房切除术转为BCS的风险比(RR)为2.40 (95% CI 1.44-4.01; p = 0.0008):结论:新辅助靶向治疗明显提高了保乳手术的实际实施率,然而,单药治疗与双HER2阻断相比,并没有统计学意义上的显著提高。
{"title":"Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis.","authors":"Manlu Cui, Juan Fu, Qiuyun Li","doi":"10.1186/s12885-024-13052-5","DOIUrl":"10.1186/s12885-024-13052-5","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant targeted therapy has shown that improve pathologic complete response and facilitate breast-conserving surgery, but the difference between single-agent treatment or dual-HER2 blockade to the conversion of breast-conserving surgery has not been well described.</p><p><strong>Methods: </strong>Via the systematic literature search of PubMed, Web of Science and Cochrane Library databases, 5 eligible studies used to perform this meta-analysis, which was carried out using RevMan version 5.4.</p><p><strong>Results: </strong>A total of 1306 patients from five randomized controlled trials were included in the analysis, revealing a significant increase in the conversion rate to breast-conserving surgery with neoadjuvant targeted therapy (OR 0.30, 95% CI 0.15-0.57; p = 0.0003). The odds ratio (OR) for single-agent treatment compared to dual-HER2 blockade was 1.04 (95% CI 0.73-1.48; p = 0.82). For pathological complete response (pCR), the OR for single-HER2 blockade versus dual-HER2 blockade was 0.43 (95% CI 0.34-0.55; p = 0.01), and for clinical response, it was 0.81 (95% CI 0.59-1.10; p = 0.17). The OR for serious adverse events between single-HER2 and dual-HER2 blockade was 0.72 (95% CI 0.55-0.95; p = 0.02). The risk ratio (RR) for pCR and the shift from mastectomy to BCS was 1.16 (95% CI 0.78-1.72; p = 0.47), while for clinical response and the shift from mastectomy to BCS, it was 2.40 (95% CI 1.44-4.01; p = 0.0008).</p><p><strong>Conclusion: </strong>Neoadjuvant targeted treatment obviously promote the actual implementation rate of breast-conserving surgery, nevertheless, there was no statistically significant increase in single-agent treatment versus dual-HER2 blockade.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11490152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study. 使用稀有细胞分拣机检测肺癌患者体内的循环肿瘤细胞:一项试验研究。
IF 3.4 2区 医学 Q2 ONCOLOGY Pub Date : 2024-10-18 DOI: 10.1186/s12885-024-12945-9
Kazuto Sugai, Tomoko Mori, Turan Bilal, Atsuko Furukawa, Yasuharu Sekine, Naohiro Kobayashi, Shinji Kikuchi, Yukinobu Goto, Hideo Ichimura, Taisuke Masuda, Fumihito Arai, Yukio Sato, Satoshi Matsusaka

Background: We developed a Rare Cell Sorter (RCS) for collecting single cell including circulating tumor cells (CTCs). This single-institution pilot study evaluated the ability of this device to detect tumor-like cells in patients with lung cancer and confirmed their genuineness based on the epidermal growth factor receptor (EGFR) mutation concordance with tissue samples.

Methods: This study included patients treated for lung cancer from September 2021 to August 2022 in University of Tsukuba Hospital. Peripheral blood samples were obtained before surgery or during periodic medical checks for patients treated with drugs. We used the RCS to capture cells based on size. The cells were stained, and the Hoechst-positive, CD45-negative, and epithelial celladhesion molecule (EpCAM)- positive cells were defined as CTCs, were collected. The presumptive CTCs were counted and tested using digital droplet polymerase chain reaction for EGFR mutations and compared with the tissue EGFR status to check concordance.

Results: Eighteen patients were included in this study and CTCs were detected in 6 patients (33%). The CTCs from three patients showed EGFR mutation, and the EGFR mutation status of CTCs concorded with that of tissue samples in 83% of the cases (5/6). Only one CTC showed a different status from the tissue, and the concordance rate of EGFR status between CTCs and the tissue was 96% (24/25).

Conclusion: The ability of the RCS to detect CTCs in patients with lung cancer was demonstrated based on the concordance of EGFR status in this pilot study. This novel hybrid method of CTC recovery using the RCS has the potential to recover a wide range of CTCs regardless of EpCAM. Further validation through a large-scale study is needed.

背景:我们开发了一种稀有细胞分拣机(RCS),用于收集包括循环肿瘤细胞(CTC)在内的单细胞。这项单机构试点研究评估了该设备检测肺癌患者肿瘤样细胞的能力,并根据表皮生长因子受体(EGFR)突变与组织样本的一致性确认了这些细胞的真实性:研究对象包括 2021 年 9 月至 2022 年 8 月期间在筑波大学医院接受治疗的肺癌患者。对接受药物治疗的患者,在手术前或定期体检时采集外周血样本。我们使用 RCS 根据细胞大小捕获细胞。对细胞进行染色,收集 Hoechst 阳性、CD45 阴性和上皮细胞粘附分子(EpCAM)阳性的细胞,定义为 CTCs。对推测的 CTC 进行计数,并使用数字液滴聚合酶链反应检测表皮生长因子受体(EGFR)突变,与组织中的 EGFR 状态进行比较,以检查一致性:本研究共纳入 18 名患者,其中 6 名患者(33%)检测到了 CTC。3名患者的CTC显示表皮生长因子受体(EGFR)突变,83%的病例(5/6)的CTC与组织样本的EGFR突变状态一致。只有1例CTC与组织样本的EGFR突变状态不同,CTC与组织样本的EGFR突变状态一致率为96%(24/25):结论:在这项试点研究中,基于表皮生长因子受体状态的一致性,证明了 RCS 检测肺癌患者 CTC 的能力。这种利用 RCS 回收 CTC 的新型混合方法有可能回收各种 CTC,而不受 EpCAM 的影响。还需要通过大规模研究进一步验证。
{"title":"Detection of circulating tumor cells in patients with lung cancer using a rare cell sorter: a pilot study.","authors":"Kazuto Sugai, Tomoko Mori, Turan Bilal, Atsuko Furukawa, Yasuharu Sekine, Naohiro Kobayashi, Shinji Kikuchi, Yukinobu Goto, Hideo Ichimura, Taisuke Masuda, Fumihito Arai, Yukio Sato, Satoshi Matsusaka","doi":"10.1186/s12885-024-12945-9","DOIUrl":"https://doi.org/10.1186/s12885-024-12945-9","url":null,"abstract":"<p><strong>Background: </strong>We developed a Rare Cell Sorter (RCS) for collecting single cell including circulating tumor cells (CTCs). This single-institution pilot study evaluated the ability of this device to detect tumor-like cells in patients with lung cancer and confirmed their genuineness based on the epidermal growth factor receptor (EGFR) mutation concordance with tissue samples.</p><p><strong>Methods: </strong>This study included patients treated for lung cancer from September 2021 to August 2022 in University of Tsukuba Hospital. Peripheral blood samples were obtained before surgery or during periodic medical checks for patients treated with drugs. We used the RCS to capture cells based on size. The cells were stained, and the Hoechst-positive, CD45-negative, and epithelial celladhesion molecule (EpCAM)- positive cells were defined as CTCs, were collected. The presumptive CTCs were counted and tested using digital droplet polymerase chain reaction for EGFR mutations and compared with the tissue EGFR status to check concordance.</p><p><strong>Results: </strong>Eighteen patients were included in this study and CTCs were detected in 6 patients (33%). The CTCs from three patients showed EGFR mutation, and the EGFR mutation status of CTCs concorded with that of tissue samples in 83% of the cases (5/6). Only one CTC showed a different status from the tissue, and the concordance rate of EGFR status between CTCs and the tissue was 96% (24/25).</p><p><strong>Conclusion: </strong>The ability of the RCS to detect CTCs in patients with lung cancer was demonstrated based on the concordance of EGFR status in this pilot study. This novel hybrid method of CTC recovery using the RCS has the potential to recover a wide range of CTCs regardless of EpCAM. Further validation through a large-scale study is needed.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BMC Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1